FATE
FATE clinical trials: FATE THERAPEUTICS INC
Every trial on ClinicalTrials.gov where FATE THERAPEUTICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 25
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FATE on the catalyst calendar · FATE registry changes
- Primary completion Jul 1, 2029Sponsor estimatePhase 2NCT07570862A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisFate Therapeutics · Lupus NephritisRecruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 1/Phase 2NCT07800871FT839 in Autoimmune DiseasesFate Therapeutics · ANCA-Associated Vasculitis (AAV)RecruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics · Non-Small Cell Lung CancerRecruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT06308978A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseFate Therapeutics · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)RecruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2025ActualPhase 1NCT04629729FT819 in Subjects With B-cell MalignanciesFate Therapeutics · Lymphoma, B-CellActive, not recruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2024ActualPhase 1NCT05182073FT576 in Subjects With Multiple MyelomaFate Therapeutics · Multiple MyelomaCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2029Sponsor estimatePhase 1NCT06241456FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · Advanced Solid TumorRecruitingFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2025ActualPhase 1NCT05950334FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)Fate Therapeutics · Relapsed/Refractory B-Cell LymphomaCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 27, 2023ActualPhase 1NCT04245722FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesFate Therapeutics · Lymphoma, B-CellTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2023ActualPhase 1NCT04023071FT516 in Subjects With Advanced Hematologic MalignanciesFate Therapeutics · Acute Myelogenous LeukemiaTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2023ActualPhase 1NCT05395052FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · Non Small Cell Lung CancerTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2023ActualPhase 1NCT05069935FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · Solid Tumor, AdultTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2023ActualPhase 1NCT04614636FT538 in Subjects With Advanced Hematologic MalignanciesFate Therapeutics · Acute Myeloid LeukemiaTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2023ActualPhase 1NCT04551885FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate Therapeutics · Solid Tumor, AdultTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2023ActualNo phase registeredNCT04106167Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyFate Therapeutics · Advanced Solid TumorTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2026Sponsor estimatePhase 1NCT05934097FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaFate Therapeutics · Diffuse Large B Cell LymphomaWithdrawnFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2022ActualPhase 1NCT03841110FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate Therapeutics · Advanced Solid TumorsCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2020ActualPhase 1/Phase 2NCT02743351Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesFate Therapeutics · Hematologic MalignanciesCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 9, 2020ActualNo phase registeredNCT04093622Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular ImmunotherapyFate Therapeutics · Hematological MalignancyTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2016ActualPhase 2NCT01627314The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With...Fate Therapeutics · Hematologic MalignanciesTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2020ActualPhase 1NCT03319459FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsFate Therapeutics · HER2 Positive Gastric CancerCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1NCT02354443A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic DisordersFate Therapeutics · Metabolic DisordersTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1NCT02354417A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic MalignanciesFate Therapeutics · Hematologic MalignanciesTerminatedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2013ActualPhase 1NCT01527838Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitFate Therapeutics · Non-Hodgkin's Lymphoma (NHL)CompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 1NCT00890500Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.Fate Therapeutics · Hematologic MalignanciesCompletedFATELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner